KR950005327A - 임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자 - Google Patents
임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자 Download PDFInfo
- Publication number
- KR950005327A KR950005327A KR1019940018956A KR19940018956A KR950005327A KR 950005327 A KR950005327 A KR 950005327A KR 1019940018956 A KR1019940018956 A KR 1019940018956A KR 19940018956 A KR19940018956 A KR 19940018956A KR 950005327 A KR950005327 A KR 950005327A
- Authority
- KR
- South Korea
- Prior art keywords
- aicd2
- bab
- mab
- bispecific antibody
- antibody
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract 10
- 102000036639 antigens Human genes 0.000 title claims abstract 10
- 108091007433 antigens Proteins 0.000 title claims abstract 10
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 6
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 title 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract 7
- 210000004698 lymphocyte Anatomy 0.000 claims abstract 3
- 210000004881 tumor cell Anatomy 0.000 claims 7
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 238000001212 derivatisation Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000006911 enzymatic reaction Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
Abstract
본 발명읜 임파구 CD2 항원 및 기타 가변 종양 항원을 인식하는 매우 효과적인 신규의 이특이적 항체 단편에 관한 것이다. 더욱이 본 발명은 AICD2. M1 및 AICD2. M2로 명명된 2개의 신규 모노클론 항체에 관한 것이다. 이들중 최소한 하나가 이특이적 항체 단편인 이들항체의 결합은 종양 치료 및 진단 분야에 성공적으로 사용될 수 있다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (14)
- BAb<X, AICD2.M1>Y 또는 BAb<X, AICD2.M2>Y로 표시되는, 종양 세포의 에피토프에 대한 제1결합 부위 및 CD2 항원의 에피토프에 대한 제2결합 부위를 포함하는, 종양 세포의 용해에 유용한 이특이적 항체 분자 : 상기 표식에서, BAb는 이특이적 항체를 의미하고, X는 종양 항원을 인식하는 항체 결정기이고, AICD2.M1 및 AICD2.M2는 CD2 항원을 인식하는 항체이고, Y는 전체 항체의 일부이다.
- 제1항에 있어서, X가 모노클론 항체 MAb 425, MAb 361 또는 MAb 15로부터 유도되는 항체 결정기인 이특이적 항체 분자.
- 제1항 또는 제2항에 있어서, Y가 F(ab′)2 분자인 이특이적 항체 분자.
- 제1항 또는 제3항중 어느 한 항에 있어서, BAb<425, AICD2.M1>F(ab′)2, BAb<425, AICD2.M2>F(ab′)2, BAb<361, AICD2.M1>F(ab′)2, BAb<361, AICD2.M2>F(ab′)2, BAb<15, AICD2.M1>F(ab′)2, 및 BAb<15, AICD2.M2>F(ab′)2로 구성되는 군으로부터 선택되는 이특이적 항체 분자.
- 하나 또는 그 이상의 이황화 결합에 의해 연결된, 각각 2개의 동일한 L(경쇄-H(중쇄) 반(half) 분자를 포함하는 2개의 다른 모노클론 항체를 2개의 F(ab′)2 분자로 효소적 방법에 의해 전환시키고, 환원 조건하에서 각 F(ab′) 분자를 Fab′티올로 절단시키고, 이러한 각 항체의 Fab′분자중의 하나를 티올 활성화제로 유도체화하고, 종양 특이성을 가지는 활성화된 Fab′분자를 임파구 특이성을 가지는 비-활성화된 Fab′분자와 결합시키거나 또는 그 역으로 결합시켜 원하는 이특이적 항체 F(ab′)2 단편을 얻음으로써, 종양 세포의 에피토프에 대한 제1결합 부위 및 CD2항원의 에피토프에 대한 제2결합 부위를 포함하며, 모노클론 항체 AICD2.M1 및 AICD2.M2를 임파구 항원을 인식하는 항체로서 사용함을 특징으로 하는, 종양 세포의 용해에 유용한 이특이적 항체 F(ab′)단편의 제조방법.
- 제5항에 있어서, MAb 425, MAb 361 또는 MAb 15를 종양 세포를 인식하는 항체로 사용함을 특징으로 하는 방법.
- 세포주 1H 10(국제 기탁번호 DSM ACC2118)로부터 단리하여 얻어질 수 있는, 항원 CD2를 인식하는 모노클론 항체 AICD2.M1.
- 세포주 7D 3(국제 기탁번호 DSM ACC2119)로부터 단리하여 얻어질 수 있는, 항원 CD2를 인식하는 모노클론 항체 AICD2.M2.
- 하나 또는 그 이상의 약학적으로 허용가능한 담체, 부형제 또는 희석제와 함께, 제1항 내지 제4항 중 어느 한 항에 따른 하나 이상의 이특이적 항체 단편을 활성 성분으로서 포함하는 약학 제제.
- 이특이적 항체 단편 BAb<X, AICD2.M2>Y를 포함하는 제9항에 따른 제1약학 제제(I) 및 MAb AICD2.M1 또는 MAb<AICD2.M2>Y 또는 BAb<X, AICD2.M1>Y(여기서, X 및 Y는 제1항에서 정의한 바와 같다)를 포함하는 별도의 제2약학제제를 포함하는 약학적 킷트.
- 이특이적 항체 단편 BAb<X, AICD2.M1>Y를 포함하는 제9항에 따른 제1약학 제제 및 MAb AICD2.M2 또는 MAb<AICD2.M2>Y 또는 BAb<X, AICD2.M2>Y(여기서, X 및 Y는 제1항에서 정의한 바와 같다)를 포함하는 별도의 제2약학제제를 포함하는 약학적 킷트.
- 제11항에 있어서, 제제(I)이 이특이적 항체 단편 BAb<425, AICD2.M1>F(ab′)2 또는 BAb<361, AICD2.M1>F(ab′)2 또는 BAb<15, AICD2.M1>F(ab′)2를 포함하고, 제제(II)가 MAb<AICD2.M2>F(ab′)2를 포함하는 약학적 킷트.
- 부가적인 T-임파구의 임의적 존재하에 제10항 내지 제12항중 어느 한 항에 따른 약학적 킷트를 이용하여 종양 세포를 제제 (I)으로 처리한 후 제제(II)로 처리한 다음, 임의적으로 기존의 정제단계를 수행하는, 자가유래 골수 이식에서 생체의 종양 세포의 정화방법.
- 사람의 종양 치료 약물을 제조하기 위한, 제1항 내지 제4항중 어느 한 항에 따른 이특이적 항체 단편의 용도.※참고사항:최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93112330 | 1993-08-02 | ||
EP93112330.1 | 1993-08-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR950005327A true KR950005327A (ko) | 1995-03-20 |
KR100347465B1 KR100347465B1 (ko) | 2003-03-03 |
Family
ID=8213129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940018956A KR100347465B1 (ko) | 1993-08-02 | 1994-08-01 | 임파구항원cd2및종양항원을인식하는이특이적트리거분자 |
Country Status (20)
Country | Link |
---|---|
US (1) | US5798229A (ko) |
EP (1) | EP0637593B1 (ko) |
JP (2) | JP3822653B2 (ko) |
KR (1) | KR100347465B1 (ko) |
AT (1) | ATE199378T1 (ko) |
AU (1) | AU683659B2 (ko) |
CA (1) | CA2129183C (ko) |
CZ (1) | CZ291071B6 (ko) |
DE (1) | DE69426743T2 (ko) |
DK (1) | DK0637593T3 (ko) |
ES (1) | ES2156587T3 (ko) |
GR (1) | GR3035926T3 (ko) |
HU (1) | HU218100B (ko) |
NO (1) | NO942850L (ko) |
PL (1) | PL176761B1 (ko) |
PT (1) | PT637593E (ko) |
RU (1) | RU2203319C2 (ko) |
SK (1) | SK283133B6 (ko) |
UA (1) | UA40577C2 (ko) |
ZA (1) | ZA945753B (ko) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0826696T3 (da) * | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
EP0826695B1 (de) * | 1996-09-03 | 2001-12-12 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Zerstörung von kontaminierenden Tumorzellen in Stammzelltransplantaten mit bispezifischen Antikörpern |
US6863887B1 (en) * | 1998-03-30 | 2005-03-08 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
JP4786793B2 (ja) | 1998-03-30 | 2011-10-05 | ノースウエスト バイオセラピューティクス,インコーポレイティド | 腫瘍形成におけるcxcr−4遺伝子の役割に基く治療的および診断的応用 |
DE69931926T2 (de) * | 1998-07-10 | 2007-02-01 | Connex Gmbh | Immunologisches reagens, das spezifisch mit der extrazellulären domäne der menschlichen zeta-kette reagiert |
WO2000018806A1 (de) * | 1998-09-25 | 2000-04-06 | Horst Lindhofer | Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren |
HU228477B1 (en) | 1999-08-23 | 2013-03-28 | Dana Farber Cancer Inst Inc | Pd-1, a receptor for b7-4, and uses therefor |
MXPA03008959A (es) | 2001-04-02 | 2004-10-15 | Wyeth Corp | Pd-1, un receptor para b7-4 y sus usos. |
AT502293B1 (de) * | 2002-05-15 | 2008-03-15 | Igeneon Krebs Immuntherapie | Immunogener, monoklonaler antikörper |
CA2497628A1 (en) * | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
ATE502051T1 (de) | 2002-10-16 | 2011-04-15 | Purdue Pharma Lp | Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung |
JP2007525446A (ja) * | 2003-03-28 | 2007-09-06 | エルシス セラピューティクス, インク. | 抗体活性の転換のための方法及び組成物 |
AU2004256021A1 (en) * | 2003-05-09 | 2005-01-20 | University Of Massachusetts | Non-human animals expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor |
US20070092515A1 (en) * | 2003-11-06 | 2007-04-26 | Icos Corporation | Methods of treating chronic pain using compositions that specifically bind cd11d (alpha-d) integrin |
EP1690097A2 (en) * | 2003-12-04 | 2006-08-16 | Applied Research Systems ARS Holding N.V. | Methods for identifying modulators of active kit tyrosine kinase receptor |
WO2006050291A1 (en) * | 2004-10-29 | 2006-05-11 | Elusys Therapeutics, Inc. | Use of cr1-binding molecules in clearance and induction of immune responses |
EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
WO2007114319A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
TWI464262B (zh) | 2007-09-26 | 2014-12-11 | 中外製藥股份有限公司 | 抗體固定區的變異 |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
US8242247B2 (en) * | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
EP4160212B1 (en) | 2008-01-15 | 2024-04-17 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
EP3133086B1 (en) | 2008-09-26 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
EP3903829B1 (en) | 2009-02-13 | 2023-05-03 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
KR101431318B1 (ko) | 2009-04-02 | 2014-08-20 | 로슈 글리카트 아게 | 전장 항체 및 단일쇄 fab 단편을 포함하는 다중특이성 항체 |
CA2757931C (en) | 2009-04-07 | 2019-03-26 | Roche Glycart Ag | Trivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
EP2477648B1 (en) | 2009-09-15 | 2022-07-20 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
SG179196A1 (en) | 2009-09-16 | 2012-04-27 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
JP5837821B2 (ja) | 2009-09-24 | 2015-12-24 | 中外製薬株式会社 | 抗体定常領域改変体 |
CA2778953C (en) | 2009-11-13 | 2020-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
CA2782194C (en) | 2009-12-02 | 2018-01-16 | Immunomedics, Inc. | Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer |
CN102753194B (zh) * | 2009-12-02 | 2015-07-08 | 伊麦吉纳博公司 | 靶向人前列腺特异性膜抗原的j591微抗体和双抗体 |
RS58693B1 (sr) | 2009-12-10 | 2019-06-28 | Hoffmann La Roche | Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena |
JP6087054B2 (ja) * | 2009-12-25 | 2017-03-01 | 中外製薬株式会社 | ポリペプチド多量体を精製するためのポリペプチドの改変方法 |
EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
TWI586806B (zh) * | 2010-04-23 | 2017-06-11 | 建南德克公司 | 異多聚體蛋白質之製造 |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
ES2660151T3 (es) | 2010-11-17 | 2018-03-21 | Chugai Seiyaku Kabushiki Kaisha | Molécula de unión a antígeno multiespecífica que tiene función alternativa a la función del factor VIII de coagulación sanguínea |
KR102244173B1 (ko) | 2010-11-30 | 2021-04-26 | 추가이 세이야쿠 가부시키가이샤 | 세포상해 유도 치료제 |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
JP5764677B2 (ja) | 2011-02-28 | 2015-08-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗原結合タンパク質 |
TWI803876B (zh) * | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
CA2831572C (en) | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
KR102492792B1 (ko) * | 2011-10-11 | 2023-01-30 | 제넨테크, 인크. | 이중특이적 항체의 개선된 어셈블리 |
RU2658603C2 (ru) * | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
BR112014019579A2 (pt) | 2012-02-10 | 2019-10-15 | Genentech, Inc | Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero |
CA2871880A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
RU2015100656A (ru) | 2012-06-27 | 2016-08-20 | Ф. Хоффманн-Ля Рош Аг | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения |
EP3613765A1 (en) | 2012-08-03 | 2020-02-26 | Dana-Farber Cancer Institute, Inc. | Antibody against repulsive guidance molecule b (rgmb) |
WO2014028560A2 (en) | 2012-08-14 | 2014-02-20 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
HUE057977T2 (hu) | 2012-12-13 | 2022-06-28 | Immunomedics Inc | Ellenanyagok és SN-38 immunkonjugátumainak dózisai javított hatásossággal és csökkentett toxicitással |
US20160122829A1 (en) | 2013-06-06 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using PD-L1 Isoforms |
EP3027225B1 (en) | 2013-07-31 | 2021-03-24 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using transforming growth factor alpha |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
KR20160044060A (ko) | 2013-10-11 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | 다중특이적 도메인 교환된 통상의 가변 경쇄 항체 |
US11708411B2 (en) | 2013-12-20 | 2023-07-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
WO2015105995A2 (en) | 2014-01-08 | 2015-07-16 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
CN106132436B (zh) | 2014-02-21 | 2021-06-15 | Ibc药品公司 | 通过诱导对trop-2表达细胞的免疫应答的疾病疗法 |
CN106029098A (zh) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | 人源化rfb4抗cd22抗体 |
IL278350B (en) | 2014-04-03 | 2022-06-01 | Igm Biosciences Inc | J-chain qualified |
EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
KR20220025917A (ko) * | 2014-05-29 | 2022-03-03 | 마크로제닉스, 인크. | 삼중-특이적 결합 분자 및 그것의 사용 방법 |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
AU2015328370B2 (en) | 2014-10-07 | 2021-08-05 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
CA2968352A1 (en) | 2014-12-08 | 2016-06-16 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents |
ES2874558T3 (es) | 2015-03-04 | 2021-11-05 | Igm Biosciences Inc | Moléculas de unión a CD20 y usos de las mismas |
KR20180026659A (ko) | 2015-03-18 | 2018-03-13 | 더 존스 홉킨스 유니버시티 | 포타슘 채널 kcnk9를 표적화하는 신규한 모노클로날 항체 억제제 |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
JP6746845B2 (ja) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け |
CN114796501A (zh) | 2015-06-25 | 2022-07-29 | 免疫医疗公司 | 抗体与治疗剂的组合治疗癌症的方法 |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
EP3355913A1 (en) | 2015-09-30 | 2018-08-08 | IGM Biosciences A/S | Binding molecules with modified j-chain |
EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
EP3362074B1 (en) | 2015-10-16 | 2023-08-09 | President and Fellows of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
AU2017238054B2 (en) | 2016-03-21 | 2023-10-19 | Dana-Farber Cancer Institute, Inc. | T-cell exhaustion state-specific gene expression regulators and uses thereof |
EP3504239A1 (en) | 2016-08-25 | 2019-07-03 | H. Hoffnabb-La Roche Ag | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
CN110072553B (zh) | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
RU2663104C1 (ru) * | 2017-07-13 | 2018-08-01 | Общество с ограниченной ответственностью "Реал Таргет" | Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей |
WO2020236797A1 (en) * | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
JPWO2022239720A1 (ko) | 2021-05-10 | 2022-11-17 | ||
WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
WO2023097119A2 (en) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
WO2024059183A1 (en) | 2022-09-14 | 2024-03-21 | President And Fellows Of Harvard College | Methods and compositions for modulation of piezo1 in the treatment of cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE260880T1 (de) * | 1986-09-11 | 1988-11-03 | Dana-Farber Cancer Institute, Inc., Boston, Mass., Us | Verfahren zur ausloesung der zytotoxizitaet. |
ES2073394T3 (es) * | 1987-06-10 | 1995-08-16 | Dana Farber Cancer Inst Inc | Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares. |
WO1991003493A1 (en) * | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
JP3854306B2 (ja) * | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ヒト化及びキメラモノクローナル抗体 |
-
1994
- 1994-06-22 UA UA94005274A patent/UA40577C2/uk unknown
- 1994-07-21 EP EP94111346A patent/EP0637593B1/en not_active Expired - Lifetime
- 1994-07-21 DK DK94111346T patent/DK0637593T3/da active
- 1994-07-21 PT PT94111346T patent/PT637593E/pt unknown
- 1994-07-21 DE DE69426743T patent/DE69426743T2/de not_active Expired - Fee Related
- 1994-07-21 ES ES94111346T patent/ES2156587T3/es not_active Expired - Lifetime
- 1994-07-21 AT AT94111346T patent/ATE199378T1/de not_active IP Right Cessation
- 1994-07-26 CZ CZ19941802A patent/CZ291071B6/cs not_active IP Right Cessation
- 1994-07-26 AU AU68698/94A patent/AU683659B2/en not_active Ceased
- 1994-07-28 HU HU9402220A patent/HU218100B/hu not_active IP Right Cessation
- 1994-07-28 SK SK912-94A patent/SK283133B6/sk not_active IP Right Cessation
- 1994-07-29 CA CA002129183A patent/CA2129183C/en not_active Expired - Fee Related
- 1994-08-01 RU RU94028282/13A patent/RU2203319C2/ru not_active IP Right Cessation
- 1994-08-01 NO NO942850A patent/NO942850L/no unknown
- 1994-08-01 PL PL94304510A patent/PL176761B1/pl unknown
- 1994-08-01 KR KR1019940018956A patent/KR100347465B1/ko not_active IP Right Cessation
- 1994-08-02 US US08/284,947 patent/US5798229A/en not_active Expired - Fee Related
- 1994-08-02 ZA ZA945753A patent/ZA945753B/xx unknown
- 1994-08-02 JP JP18156894A patent/JP3822653B2/ja not_active Expired - Lifetime
-
2001
- 2001-05-25 GR GR20010400779T patent/GR3035926T3/el not_active IP Right Cessation
-
2005
- 2005-08-10 JP JP2005232483A patent/JP4231862B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NO942850D0 (ko) | 1994-08-01 |
CA2129183C (en) | 2006-05-16 |
DK0637593T3 (da) | 2001-06-25 |
AU6869894A (en) | 1995-02-09 |
ATE199378T1 (de) | 2001-03-15 |
NO942850L (no) | 1995-02-03 |
DE69426743D1 (de) | 2001-04-05 |
JPH0789873A (ja) | 1995-04-04 |
UA40577C2 (uk) | 2001-08-15 |
CA2129183A1 (en) | 1995-02-03 |
HU218100B (hu) | 2000-06-28 |
HU9402220D0 (en) | 1994-10-28 |
CZ180294A3 (en) | 1995-02-15 |
ES2156587T3 (es) | 2001-07-01 |
PL176761B1 (pl) | 1999-07-30 |
JP3822653B2 (ja) | 2006-09-20 |
EP0637593A1 (en) | 1995-02-08 |
KR100347465B1 (ko) | 2003-03-03 |
HUT71309A (en) | 1995-11-28 |
PL304510A1 (en) | 1995-02-06 |
PT637593E (pt) | 2001-08-30 |
AU683659B2 (en) | 1997-11-20 |
GR3035926T3 (en) | 2001-08-31 |
EP0637593B1 (en) | 2001-02-28 |
JP4231862B2 (ja) | 2009-03-04 |
DE69426743T2 (de) | 2001-08-16 |
JP2005336207A (ja) | 2005-12-08 |
SK91294A3 (en) | 1996-11-06 |
US5798229A (en) | 1998-08-25 |
RU94028282A (ru) | 1996-07-20 |
RU2203319C2 (ru) | 2003-04-27 |
CZ291071B6 (cs) | 2002-12-11 |
SK283133B6 (sk) | 2003-03-04 |
ZA945753B (en) | 1995-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950005327A (ko) | 임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자 | |
RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
DE60331910D1 (de) | Antikörper gegen humanes cd22 und deren therapeutische und diagnostische verwendungen | |
ATE477276T1 (de) | Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen | |
HUP0300806A2 (hu) | A humán IL-1béta-nak megfelelő antitestek | |
ECSP066526A (es) | Anticuerpos que se unen al receptor de interleuquina-4 | |
BRPI9809391B8 (pt) | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica | |
DE60224291D1 (de) | System zur antikörperexpression und- synthese | |
KR920701465A (ko) | Cd4 특이적 재조합 항체 | |
EE05496B1 (et) | Antikeha, mis seob osteoprotegeriini siduvat valku | |
DE69942148D1 (de) | Gebrauch von bispezifischen antikörpern in diagnose und therapie | |
ES2231826T3 (es) | Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis. | |
TW200500377A (en) | Method of humanizing immune system molecules | |
EP1705191A3 (en) | Anti-interleukin-18 antibody | |
DK0461177T3 (da) | Humant intra-acrosomalt spermantigen til anvendelse i en svangerskabsforebyggende vaccine | |
DE69939312D1 (de) | Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen | |
RU2013105769A (ru) | Биологические материалы и их применение | |
BR0207151A (pt) | Moléculas de aglutinação terapêuticas | |
EA200401081A1 (ru) | Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro | |
KR900013986A (ko) | 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도 | |
Sandberg et al. | Initiation of bone resorption by the classical and alternative C pathways and its mediation by prostaglandins | |
EP0350690A3 (de) | Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente | |
ATE353337T1 (de) | Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet | |
CA2449488A1 (en) | Compositions and methods for treating hyperimmune response in the eye | |
IT1284076B1 (it) | Frammenti f(ab')2 e relative immunoglobuline igg, attivi come anticorpi specifici verso farmaci e i loro metaboliti, e loro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20080701 Year of fee payment: 7 |
|
LAPS | Lapse due to unpaid annual fee |